{"title":"肿瘤干细胞抗原的鉴定及ctl介导的肿瘤免疫治疗进展。","authors":"Sho Miyamoto, Takayuki Kanaseki, Yoshihiko Hirohashi, Tomohide Tsukahara, Yasuhiro Kikuchi, Noriyuki Sato, Toshihiko Torigoe","doi":"10.2177/jsci.40.40","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.</p>","PeriodicalId":79359,"journal":{"name":"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology","volume":"40 1","pages":"40-47"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2177/jsci.40.40","citationCount":"2","resultStr":"{\"title\":\"Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy.\",\"authors\":\"Sho Miyamoto, Takayuki Kanaseki, Yoshihiko Hirohashi, Tomohide Tsukahara, Yasuhiro Kikuchi, Noriyuki Sato, Toshihiko Torigoe\",\"doi\":\"10.2177/jsci.40.40\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.</p>\",\"PeriodicalId\":79359,\"journal\":{\"name\":\"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology\",\"volume\":\"40 1\",\"pages\":\"40-47\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2177/jsci.40.40\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2177/jsci.40.40\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2177/jsci.40.40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy.
Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.